NEWS

Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
  • Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
  • December 12, 2022
Press Release
Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting
  • Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting
  • November 3, 2022
Press Release
Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer
  • Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer
  • February 16, 2022
Press Release

PRESENTATIONS

TRIAL IN PROGRESS: A PHASE 1B STUDY OF ELA026 IN PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

ASH 2022 Abstract #3730

CHARACTERIZATION OF ELA026, A CLINICAL-STAGE MONOCLONAL ANTIBODY THAT RAPIDLY AND POTENTLY DEPLETES MYELOID CELLS AND T LYMPHOCYTES

ASH 2022 Abstract #3722

IDENTIFICATION AND CHARACTERIZATION OF A RETROSPECTIVE COHORT OF SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS PATIENTS IN THE US

ASH 2022 Abstract #2415

News Coverage

A Star is born as new SIRP player aims to Electra-fy rare disease

  • By Randy Osborne, Bioworld
  • February 16, 2022
Star Therapeutics Inc. emerged from stealth mode to tell the world about its approach to drug discovery and development in rare diseases, and to spin out Electra Therapeutics Inc., the first in a projected family of companies. Deploying antibody drug discovery expertise, South San Francisco-based Star aims to generate programs that target multiple diseases with...

Star’s Electra spinout turning SIRP proteins into depletion handles

  • By Karen Tkach Tuzman, Biocentury
  • February 16, 2022
The first in a series of spinouts from Star targeting biology shared by multiple diseases, Electra is leveraging insights into the SIRP protein family to stop pathogenic myeloid and T cell activity via a clinical-stage lead program, with a series of preclinical assets behind it. Electra Therapeutics Inc. and its parent company Star Therapeutics both emerged...

Electra, one of 2 Star biotechs, snags $84M to apply brakes to ‘immune system haywire’

  • By Kyle LaHucik, Fierce Biotech
  • February 16, 2022
Electra Therapeutics, a member of the Star Therapeutics constellation, is going to be reaching for some of the 7,000 rare diseases, thanks to a new $84 million series B financing. The biotech, led by ex-True North Therapeutics executives, broke cover Wednesday with a monoclonal antibody in phase 1 trials in patients with the rare inflammatory...